INIS
patients
100%
diseases
81%
proteins
45%
therapy
28%
hypertension
27%
matrices
27%
genetics
27%
biological markers
27%
laboratories
27%
grafts
27%
host
27%
reviews
27%
covid-19
27%
transplants
27%
antigens
27%
receptors
27%
pediatrics
27%
inflammation
24%
values
18%
risks
13%
plasma
10%
leukemia
9%
range
9%
regulations
9%
immunoassay
9%
neutrophils
9%
performance
9%
units
9%
thrombosis
9%
safety
9%
lymphomas
9%
connective tissue
8%
comparative evaluations
8%
mortality
8%
levels
6%
control
6%
Keyphrases
Immune Response
29%
Systemic Immune-mediated Diseases
27%
Genetic Landscape
27%
Dilated Cardiomyopathy
27%
Dephosphorylated Uncarboxylated Matrix Gla Protein
27%
Vascular Remodeling
27%
Pulmonary Arterial Hypertension
27%
Pulmonary Hypertension
27%
Anti-CD19 chimeric Antigen Receptor T Cells
27%
Connective Tissue Disease
9%
Hypertension Patients
9%
Anti-annexin
9%
Inhibitory Immune Checkpoint
7%
Immune-mediated Inflammatory Diseases
7%
Immune Checkpoint Molecules
7%
Likely Pathogenic Variant
6%
Healthy Controls
5%
Protein Level
5%
Immunology and Microbiology
Autoantibodies
27%
Graft-Versus-Host Disease
27%
Immunity
27%
COVID-19
27%
Cell Transplantation
27%
Hematopoietic Cell
27%
Chimeric Antigen Receptor T-Cell Therapy
27%
CD19
27%
Isotype
22%
Chimeric Antigen Receptor T-Cell
16%
Chronic Graft Versus Host Disease
10%
Acute Graft Versus Host Disease
10%
Overall Survival
5%
Allogeneic Stem Cell Transplantation
5%
Axicabtagene Ciloleucel
5%
Alloimmunity
5%
T Cell
5%
Recurrence Free Survival
5%